Improving treatment options for Trichomonas vaginalis infections in men and women.
Official title: Refining Trichomonas vaginalis treatment in women and men.
Funded at Tulane University of Louisiana · NIH-11061219 · Data updated 2026-11-12
This study is looking at a new single-dose medicine called secnidazole to see if it works better than the usual multi-dose treatment for Trichomonas vaginalis, a common infection that can cause health problems, and it's for both men and women who are dealing with this issue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | April 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $1,347,276 |
| NIH project number | 5R01AI183266-02 |
| Project ID | NIH-11061219 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Trichomonas vaginalis, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients who do not have Trichomonas vaginalis or those who have already been successfully treated with current therapies may not benefit from this research.
What this research studies
This research focuses on enhancing the treatment of Trichomonas vaginalis, a common sexually transmitted infection that can lead to serious health issues. The study aims to compare the effectiveness of a new single-dose medication, secnidazole, against the current multi-dose treatment, metronidazole, which has shown high rates of treatment failure. By including both men and women in the trials, the research seeks to provide a more comprehensive understanding of effective treatments for this infection. Patients will be monitored for treatment outcomes and any potential side effects.
Why it matters
Potential benefit: If successful, this research could lead to more effective and convenient treatment options for Trichomonas vaginalis, reducing the incidence of treatment failures.
How similar studies have gone: Previous studies have shown promising results with similar treatment approaches, indicating potential for success in refining Trichomonas vaginalis treatment.
Where this research is happening
-
Tulane University of Louisiana
New Orleans, United States Active
Researchers
- Principal investigator: Kissinger, Patricia J — Tulane University of Louisiana
- Study coordinator: Kissinger, Patricia J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.